Literature DB >> 30575027

Validation of the eighth edition AJCC staging system in early T1 to T2 oral squamous cell carcinoma.

Samskruthi Murthy1, Tsu-Hui Hubert Low2, Narayana Subramaniam1, Deepak Balasubramanian1, Vidhyadharan Sivakumaran1, Adharsh Anand1, Smitha Nalumackal Vijayan3, Ajit Nambiar3, Krishnakumar Thankappan1, Subramania Iyer1.   

Abstract

BACKGROUND: To validate the newly proposed American Joint Committee on Cancer (AJCC) eighth edition staging in early T1 and T2 oral cavity cancers and its effect in predicting tumour control.
METHODS: Retrospective analysis of treatment outcomes of 441 T1 to T2 oral squamous cell carcinoma (OSCC). Overall survival (OS), disease-specific survival (DSS), and tumour control were calculated and compared between the AJCC 7 and 8 staging systems.
RESULTS: The 5-year OS was 78% and 61% for T1 and T2 tumours, respetively (P < 0.001) (AJCC 7) vs 87% and 67% (P < 0.001) (AJCC 8). The 5-year DSS was 78% and 61% for T1 and T2, respectively (P < 0.001) (AJCC 7) vs 89% and 71% (P < 0.001) (AJCC 8). For stages I and II tumours the 5-year OS was 81% and 76%, respectively (P < 0.302) (AJCC 7) vs 87% and 73% (P < 0.017) (AJCC 8). The 5-year DSS was 83% and 82% (P < 0.222) vs 89% and 77% (P < 0.016). With the AJCC eighth edition the 5-year local, regional, and distant control rates for T1 vs T2 tumours were 85% vs 74% (P = 0.003), 95% vs 77% (P = 0.001), and 95% vs 80% (P = 0.014), respectively.
CONCLUSION: The AJCC 8th staging system provided for more accurate prediction of OS, DSS, and disease control in early oral cavity cancers.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  American Joint Committee for Cancer 8; depth of invasion; squamous cell carcinoma; tongue cancer

Mesh:

Year:  2018        PMID: 30575027     DOI: 10.1002/jso.25348

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  1 in total

1.  Rehabilitation approach in oropharyngeal cancer: Case report.

Authors:  Zainab Al Lawati; Riley Smith
Journal:  SAGE Open Med Case Rep       Date:  2021-06-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.